The research group around Ralf Gilsbach presents an efficient AAV-based method for CRISPRi-mediated epigenetic silencing of gene expression in cardiac myocytes in vivo and in vitro. This functional epigenetic approach provides a novel and efficient way to modulate gene expression in the heart and could become a standard method for cardiovascular disease modeling and translational research.
Link to the publication:
In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector (Laurette et al., 2024)
Link to the Press release:
New precise instrument for researching heart muscle diseases
